Bleeding out: Theranos oozes with corporate governance lessons
A year ago, Theranos was a Silicon Valley health tech “unicorn” praised for breakthrough advancements in blood testing. Now it’s under civil and criminal investigation for defrauding investors. The role Theranos’ board has played in this is already shaping up to be a pointed object lesson for board best practices ...
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Article
LendingClub could teach Theranos a thing or two about crisis management
Relatively young, technology-based companies face special difficulties when dealing with crises. Their focus on market disruption and their lack of established credibility make earning public trust even more difficult. And yet, LendingClub shows how it can be done at a time when Theranos certainly failed the crisis management test. David ...
-
OpinionInstitutional resilience: Why remediation fails without independent governance challenge
Changing governance and internal controls in response to recent enforcement actions cannot mask a fundamental deficiency: remediation is not changing the way decisions are being made, allowing the same mistakes to happen over and over.
-
OpinionEthics as strategic value: When compliance becomes a board-level decision tool
For many Boards of Directors, compliance reporting feels familiar and reassuring. Dashboards are green. Policies are updated. Training is complete. Incidents are investigated and closed. On paper, the system works.